Advanced search
Publication Cover
Libyan Journal of Medicine Volume 14, 2019 - Issue 1
Submit an article Journal homepage
1,336
Views
1
CrossRef citations to date
0
Altmetric
Original Article

The role of tacstd-2 level in hepatitis C patients (controlled clinical research)

Memduh Sahina Department of Gastroenterology, Saglik Bilimleri University Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, TurkeyCorrespondence[email protected]
,
Aylin Yetimb Department of Adeloscent Health, Istanbul University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-4059-1760
ORCID Icon &
Fehmi Atesc Department of Gastroenterology, Mersin University, Mersin, TurkeyORCID Iconhttps://orcid.org/0000-0003-2527-414X
ORCID Icon
Article: 1622363 | Received 26 Dec 2018, Accepted 18 May 2019, Published online: 30 May 2019

References

  • Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the USA, 1999 through 2002. Ann InternMed. 2006;144:1–6.
  • Lohmann V, Körner F, Koch J-O, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatomacellline. Science. 1999;2851:10–13.
  • Barth H, Schafer C, Adah MI, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem. 2003;278:41003–41012.
  • Evans MJ, vonHahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virusco-receptor required for a late step in entry. Nature. 2007;2007(446):801–805.
  • Ploss A, Evans MJ, Gaysinskaya VA, et al. Humanoccludin is a hepatitis C virus entry factor required for infection of mousecells. Nature. 2009;12:882–886.
  • Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290–1295.
  • Mühlmann G, Spizzo G, Gostner J, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2009;62:152–158.
  • Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2008;21:186–191.
  • Ohmachi T, Tanaka F, Mimori K, et al. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006;12:3057–3063.
  • Goldstein SA, Lawson DA, Cheng D, et al. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A. 2008;105:20882–20887.
  • Okabe M, Tsukahara Y, Tanaka M, et al. Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. Development. 2009;136:1951–1960.
  • Cubas R, Zhang S, Li M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPKpathway. Mol Cancer. 2010;9:253.
  • Pak MG, Shin DH, Lee CH, et al. Significance of EpCAM and TROP2 expression in non-small cell lung cancer. World J Surg Oncol. 2012;10:53.
  • Li Z, Jiang X, Zhang W. TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun. 2016;470:197–204.
  • Chen R, Lu M, Wang J, et al. Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type. Virchows Arch. 2013;463:713–719.
  • Trerotola M, Jernigan DL, Liu Q, et al. Trop-2 promotes prostate cancer metastasis by modulating beta(1) integrin functions. Cancer Res. 2013;73:3155–3167.
  • Ning S, Liang N, Liu B, et al. TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas. Neurol Sci. 2013;34:1745–1750.
  • Sekhar V, Pollicino T, Diaz G, et al. Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly down regulated in hepatocellular carcinoma. PLoSPathog. 2018;14:e1006916.
  • Shimizu Y, Shirasago Y, Kondoh M, et al. Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model. J Virol. 2018; Apr:92(8)7;pii: JVI.02258–17.
  • Fofana I, Krieger SE, Grunert F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology. 2010;139:953–964.
  • Nakashima K, Shimada H, Ochiai T, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;20:1029–1035.
  • Wang J, Day R, Dong Y, et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008;7:280–285.
  • Hyder MA, Hasan M, Mohieldein AH. Comparative Levels of ALT, AST, ALP and GGT in Liver associated diseases. Euro J Exp Bio. 2013;3:280–284.
  • Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol. 2007;21(1):161–173.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.